- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Defining ‘Specialty Lite’ | Asembia 2024
The GLP-1s and some of the migraine drugs are included in this category of drugs that are priced to cost between $5,000 and $15,000 a year and are dispensed at a retail pharmacies, George Van Antwerp, MBA, a managing director at Deloitte, explains.
George Van Antwerp, MBA, a managing director at Deloitte, spoke with MHE prior to his presentation today at the Asembia 2024 meeting in Las Vegas.
Van Antwerp says "specialty" is a middle-ground of prescription drugs that are priced to cost between $5,000-$15,000 a year.
Some of the migraine medications, the GLP-1s for diabetes and weight loss and second-generation antipsychotics fall into the lite category. They are typically dispensed at a retail pharmacy because they don't require great degrees of special handling or administration, but they are more involved (and more expensive) than most drugs dispensed at retail pharmacies.
Also on the panel joining Van Antwerp for the discussion includes Brian Ellis, head of access and reimbursement, AbbVie; Josh Marsh, vice president and general manager, Cardinal Health Sonexus Access & Patient Support; Ronak Patel, vice president, pharmacy network operations, Asembia; and Jessica Ringena, senior vice president, Hy-Vee.
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
